Complex Structure of PDE3A–SLFN12 and Structure-based Molecular Glue Design for Apoptosis of Tumor Cells
Abstract Molecular glue is a class of small molecular drugs that mediate the protein-protein interactions. It can induce target proteins degradation or stabilization. Anagrelide, as a known phosphodiesterase 3A (PDE3A) inhibitor, is a drug used for the treatment of essential thrombocytosis. Here, we report Anagrelide induces cell death directly binding to PDE3A, which stabilizes protein Schlafen 12 (SLFN12). The high-resolution cryo-EM maps indicates that the interaction of PDE3A and SLFN12 exhibits a butterfly-like shape, to form a heterotetramer. Structure analysis showed that Anagrelide, as a new molecular glue, packs in a shallow pocket of PDE3A in the catalytic domain and the resulting modified interface binds SLFN12 through the short helix (E552-I558) of SLFN12. Based on the structure, we designed and synthesized the Anagrelide analogues with hydrophobic substitutes at 7-position. The p-tolyl substitution (compound A6) had the best improvement of around 20 folds, which IC50 is around 0.3 nM. Our studies revealed a new strategy to identify and develop a new molecular glue for targeted protein stabilization.